2005
Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder
Tordjman S, Anderson GM, Pichard N, Charbuy H, Touitou Y. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biological Psychiatry 2005, 57: 134-138. PMID: 15652871, DOI: 10.1016/j.biopsych.2004.11.003.Peer-Reviewed Original ResearchConceptsAutistic disorderNocturnal urinary excretionPineal gland hormoneLow melatonin productionNormal control individualsMelatonin physiologyGroup of childrenUrinary excretionMelatonin administrationTanner stageSleep problemsNormal controlsReported alterationNocturnal excretionControl individualsExcretion rateDisordersGland hormoneMelatoninMelatonin productionAutistic impairmentsExcretionCircadian rhythmBehavioral expressionVerbal communication
1982
Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate.
Shaywitz S, Hunt R, Jatlow P, Cohen D, Young J, Pierce R, Anderson G, Shaywitz B. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982, 69: 688-94. PMID: 7079034, DOI: 10.1542/peds.69.6.688.Peer-Reviewed Original ResearchConceptsAcute studyMPH concentrationsGrowth hormoneObserved maximal concentrationCentral dopaminergic mechanismsPeak plasma concentrationAdministration of medicationsPharmacokinetics of methylphenidatePlasma growth hormoneConcentrations of methylphenidatePlasma MPH concentrationsAttention deficit disorderClinical responseChronic treatmentDopaminergic mechanismsGroup of childrenDisorders of attentionAbbreviated Conners' Rating ScaleSchool-aged childrenOral administrationPlasma concentrationsClinical pharmacologyMPH administrationProlactin concentrationsPercentage of improvement